Viktoria Bojilova
YOU?
Author Swipe
View article: Supplementary Table S6 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Table S6 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Metastatic Sites Involved Prior to HER2-Directed Therapy.
View article: Supplementary Table S6 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Table S6 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Metastatic Sites Involved Prior to HER2-Directed Therapy.
View article: Supplementary Table S4 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Table S4 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Plasma ctDNA Alterations by Source.
View article: Supplementary Methods S1 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Methods S1 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Supplemental Methods
View article: Supplementary Figure S8 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Figure S8 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
PIK3CD S367L demonstrate increased phosphorylation of AKT. Upon progression, 1 patient developed a PIK3CD S367L mutation (location indicated in gene map), a variant of undetermined significance in the carboxy terminal C2 domain. Above, wes…
View article: Supplementary Table S1 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Table S1 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Pembrolizumab/Trastuzumab/Chemotherapy Protocol Patient Demographics
View article: Supplementary Figure S3 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Figure S3 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Response to pembrolizumab and trastuzumab induction according to pre-treatment 89Zr-trastuzumab PET avidity.
View article: Supplementary Figure S6 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Figure S6 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
HER2 heterogeneity and RTK alterations are more frequent among patients with shorter PFS. HER2 testing and tissue / plasma ctDNA NGS upon progression demonstrate that 8 of 16 (50%) of patients had HER2 negative tumors post-treatment, and 2…
View article: Data from Determinants of survival in HER2+ metastatic esophagogastric cancer
Data from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Purpose: We report updated clinical outcomes from a phase II study of pembrolizumab, trastuzumab, and chemotherapy (PTC) in metastatic esophagogastric (EG) cancer in conjunction with outcomes from an independent MSK cohort. Experimental De…
View article: Supplementary Table S2 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Table S2 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Representativeness of Study Participants.
View article: Supplementary Figure S10 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Figure S10 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Identifying intratumor clonal selection and associated resistance mechanisms. a, Inferred tumor clones paired pre-treatment and post-cycle 2 CAPOX + trastuzumab scRNA-seq demonstrates rapid clearance of highly ERBB2 expression (red) clones…
View article: Supplementary Figure S7 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Figure S7 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Baseline biopsies from a patient demonstrating significant intra-patient heterogeneity with diffusely HER2+ and PD-L1– primary tumor and HER2– but PD-L1 CPS 100 retroperitoneal lymph node with neuroendocrine differentiation.
View article: Supplementary Table S2 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Table S2 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Representativeness of Study Participants.
View article: Supplementary Data S1 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Data S1 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Supplemental Data, Spreadsheet
View article: Supplementary Figure S4 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Figure S4 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Early change in tumor-matched maxVAF in patients who received induction trastuzumab and pembrolizumab stratified by 6 month PFS (n=16 evaluable).
View article: Supplementary Figure S1 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Figure S1 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Consort diagram of HER2-directed therapy patient cohorts.
View article: Supplementary Figure S5 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Figure S5 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Lesions without pre-treatment ERBB2 amplification appear less likely to respond to pembrolizumab and trastuzumab induction. Lesion-level CT response after 1 dose of pembrolizumab and trastuzumab among patients with baseline tumor-matched c…
View article: Supplementary Figure S3 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Figure S3 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Response to pembrolizumab and trastuzumab induction according to pre-treatment 89Zr-trastuzumab PET avidity.
View article: Supplementary Table S7 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Table S7 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Univariable Cox Proportional Hazard for PFS in HER2-targeted retrospective cohort.
View article: Supplementary Figure S9 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Figure S9 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Serial plasma ctDNA in an individual patient demonstrating pre-treatment genomic heterogeneity and selection for resistant clones. Plasma ctDNA at diagnosis revealed ERBB2 amplification in a patient with HER2+ EG cancer, as well as numerou…
View article: Supplementary Table S3 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Table S3 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Correlation of 89Zr PET Uptake and HER2 Status
View article: Supplementary Figure S6 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Figure S6 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
HER2 heterogeneity and RTK alterations are more frequent among patients with shorter PFS. HER2 testing and tissue / plasma ctDNA NGS upon progression demonstrate that 8 of 16 (50%) of patients had HER2 negative tumors post-treatment, and 2…
View article: Supplementary Methods S1 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Methods S1 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Supplemental Methods
View article: Supplementary Table S7 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Table S7 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Univariable Cox Proportional Hazard for PFS in HER2-targeted retrospective cohort.
View article: Supplementary Figure S7 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Figure S7 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Baseline biopsies from a patient demonstrating significant intra-patient heterogeneity with diffusely HER2+ and PD-L1– primary tumor and HER2– but PD-L1 CPS 100 retroperitoneal lymph node with neuroendocrine differentiation.
View article: Supplementary Data S1 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Data S1 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Supplemental Data, Spreadsheet
View article: Supplementary Table S8 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Table S8 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Multivariable Cox Proportional Hazard for PFS in HER2-targeted retrospective cohort (n=217).
View article: Supplementary Table S5 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Table S5 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Genes with Oncogenic Alterations Identified by MSK-IMPACT with Frequency > 5%.
View article: Supplementary Table S1 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Table S1 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Pembrolizumab/Trastuzumab/Chemotherapy Protocol Patient Demographics
View article: Supplementary Table S5 from Determinants of survival in HER2+ metastatic esophagogastric cancer
Supplementary Table S5 from Determinants of survival in HER2+ metastatic esophagogastric cancer Open
Genes with Oncogenic Alterations Identified by MSK-IMPACT with Frequency > 5%.